Actively Recruiting
Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
Led by The Cleveland Clinic · Updated on 2025-11-25
30
Participants Needed
1
Research Sites
373 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Inflammatory responses in response to alcohol have been identified as contributing to the development of alcoholic hepatitis. The inflammatory response including that to LippoPolySaccharide is known to lead to progression of alcoholic liver disease. In addition to the inflammatory response mitochondrial perturbations exist and redox homeostasis is altered in patients with alcoholic hepatitis. Though this is known there have been very few studies targeting mitochondrial function in Peripheral Blood Mononuclear Cells (PBMCs). We plan to collect 50 milliliters of blood from healthy control patients so that we can compare the data to that of patients with alcoholic hepatitis and those who are heavy drinkers without liver disease. In addition to studying mitochondrial function we will investigate cytokine response, as well as fatty acid metabolism, glucose, and insulin measurements
CONDITIONS
Official Title
Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of alcoholic hepatitis confirmed by imaging, biochemical values, or liver biopsy along with drinking history
- Heavy drinking defined as >40 g/day or >280 g/week for women and >60 g/day or >420 g/week for men for at least 6 months and within 4 weeks prior to enrollment
- Age between 21 and 65 years
You will not qualify if you...
- Inability or unwillingness to sign informed consent
- History of cancer
- Autoimmune disease that may affect study data as judged by the principal investigator
- For control subjects: INR must be less than 1.4
- For control subjects: Total bilirubin levels less than 3
- No prior known alcoholic liver disease
- No hepatosplenomegaly or signs of liver disease based on physical exam or imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Actively Recruiting
Research Team
A
Annette Bellar
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here